Navigation Links
Molecular mechanism of anaphylactic shock decoded
Date:1/28/2009

Researchers at Heidelberg University have found a molecular mechanism for anaphylactic shock. The activation of specific proteins in the cell walls of small blood vessels plays an important role. Suppressing the respective genes protects mice from the potentially fatal reactions of the immune and circulatory systems (anaphylactic shock) without disrupting circulatory regulation. This paves the way for the development of new drugs for the treatment and prevention of anaphylactic shock.

The study by Professor Dr. Stefan Offermanns, Medical Director of the Institute of Pharmacology at Heidelberg University, and his study group in cooperation with colleagues at the German Cancer Research Center in Heidelberg as well as at Frankfurt University and the Max Planck Institute in Bad Nauheim was published online in "The Journal of Experimental Medicine".

Anaphylactic shock is an acute, life-threatening allergic reaction, usually brought on by medication, insect stings, or other allergens, which has become more frequent in recent decades. In sensitized persons, the presence of the allergen leads to the release of various substances (mediators) from immune cells in the blood. These mediators, e.g. histamine or leukotriene, cause an abrupt drop in blood pressure, lowering of body temperature, arrhythmia, respiratory distress, and acute reactions in stomach, bowels and skin. The combination of reactions leads to the life-threatening situation known as anaphylactic shock.

The mediators develop their effect via so-called G protein-coupled receptors that are found on different body cells, among others, in the walls of blood vessels. They trigger signals in the cells that then cause the typical symptoms of an anaphylactic reaction. "In the genetic mouse model, we showed that surprisingly, selective suppression of the genes coding for the G proteins Gq and G11 in vessel walls protected the animals from the most severe anaphylactic reactions
'/>"/>

Contact: Dr. Stefan Offermanns
stefan.offermann@pharma.uni-heidelberg.de
0049-622-154-8246
University Hospital Heidelberg
Source:Eurekalert  

Page: 1 2

Related biology news :

1. New molecular regulators of hyperthyroidism and goiter
2. Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. New molecular clock from LLNL and CDC indicates smallpox evolved earlier than believed
5. Story ideas from Molecular & Cellular Proteomics
6. Lets talk -- new paradigms in the research of the biomolecular composition of water
7. Scientists unveil structure of molecular target of many drugs
8. Potential new therapeutic molecular target to fight cancer
9. NIH selects LIAI for major study on allergy molecular causes and possible treatments
10. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
11. Leading cause of death in preemies might be controlled by resetting a molecular switch
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecular mechanism of anaphylactic shock decoded
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Ghanaian Obstetrics and Gynecology residents say in-country training programs ... country to practice medicine, new University of Michigan research ... in developing countries is a key component to improving ... which aim to decrease maternal and child mortality. But ...
... Harvard-Affiliated McLean Hospital have been awarded a $1.9 million ... their research into creating human induced pluripotent (iPS) stem ... of cancer and other problems associated with other options ... made possible through the American Recovery and Reinvestment Act ...
... Department of the Interior, the National Oceanic and Atmospheric ... the BP/Deepwater Horizon oil spill announced today they have ... the Natural Resource Damage Assessment, a legal process to ... compensate the public for harm to natural resources and ...
Cached Biology News:In-country OB/GYN training programs contributed to retention of doctors in Ghana, U-M study shows 2In-country OB/GYN training programs contributed to retention of doctors in Ghana, U-M study shows 3McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Calif., March 3 WaferGen Biosystems,Inc. (OTC Bulletin ... genotyping, cell biology and stem cell research systems,today ... company,s management,team. Kumar Kastury, Ph.D., director of assay ... development and John McEntee, director,of engineering, has been ...
... 3 NicOx S.A.,(Euronext Paris: COX) today announced ... the United States, which will assess the blood,pressure ... naproxen,using the Ambulatory Blood Pressure Monitoring (ABPM) technique. ... will together recruit a,total of around 420 osteoarthritis ...
... 2007 Revenue Increases 45% Recurring Disposables, ... Update on Partnered Magnetic Irrigated Catheter Launch Provided, ... reported financial results for the fourth quarter and full ... 2007, revenue increased 45% to $39.3 million,compared with $27.2 ...
Cached Biology Technology:WaferGen Announces Management Team Promotions 2WaferGen Announces Management Team Promotions 3WaferGen Announces Management Team Promotions 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Biology Products: